Pliant Therapeutics, Inc.: CMO David Raben received 575,000 shares

What happened David Raben, chief medical officer, received 575,000 derivative shares as an award at $0.00 per share (total reported value $0.00) on Oct 1, 2026. The Form 4 was filed on Oct 2, 2026.

Key details

• Transaction date: Oct 1, 2026; transaction code A (award/grant); price $0.00; amount 575,000 shares.
• Shares owned after the transaction: not reported in the filing.
• Footnote F1 (vesting): 25% of the shares vest and become exercisable on Sep 30, 2027; the remaining 75% vest in substantially equal installments on each monthly anniversary of Sep 30, 2027 (or the last day of the month if no corresponding day) over 3 years, subject to continuous service.
• Filing date: Oct 2, 2026.

Why it may matter

• The filing reports an award of derivative securities (an acquisition at no cash cost).
• A filing does not show why the insider traded or why the company acted.